| Business Summary | | Viragen,
Inc.
researches,
develops
and
manufactures
pharmaceutical
drugs
including
natural
human
interferon
and
human
monoclonal
antibodies
for
the
treatment
of
many
life-threatening
diseases
such
as
hepatitis
C,
multiple
sclerosis
and
cancer.
In
addition
to
developing
proprietary
drugs,
Viragen
is
engaged
in
a
project
designed
to
deliver
efficient,
cost-effective
alternatives
for
the
large-scale
production
of
protein-based
drugs.
Viragen
holds
the
exclusive
license
to
commercialize
Avian
Transgenic
Production
Technology
granted
by
the
Roslin
Institute
in
Scotland,
which
created
"Dolly
the
Sheep."
The
Avian
Project
is
designed
to
produce
protein-based
drugs,
including
monoclonal
antibodies
to
fight
cancer,
inside
the
eggs
of
transgenic
chickens.
Viragen's
current
collaborative
partners
include
The
Roslin
Institute,
Memorial
Sloan-Kettering
Cancer
Center,
The
National
Institutes
of
Health
(NIH),
The
United
Kingdom's
Cancer
Research
Campaign,
Pall
Corporation
and
America's
Blood
Centers. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Viragen,
Inc.
engages
in
the
research,
development,
and
manufacture
of
immunological
products,
particularly
human
leukocyte
interferon
for
antiviral
and
therapeutic
applications.
For
the
nine
months
ended
3/31/01,
revenues
totaled
$604
thousand,
up
from
$62
thousand.
Net
loss
applicable
to
Common
decreased
18%
to
$7.4
million.
Revenues
reflect
increased
interest
income.
Net
loss
was
partially
offset
by
higher
R&D
costs
due
to
development,
scale-up
and
clinical
trial
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Gerald Smith, 69 Chairman,
Pres, and CEO | $282K | $369K | Robert Zeiger, 56 Vice
Chairman | -- | -- | Dennis Healey, 52 CFO,
Treasurer, Exec. VP, Director | 252K | 22K | D. Magnus Nicolson, Ph.D., 40 COO | 170K | 42K | Melvin Rothberg, 53 Exec.
VP | 160K | 144K | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|